Compare National Beverage Corp. (FIZZ) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs TransMedics Group Inc — how do they compare? National Beverage Corp. trades at $30.9 (market cap $2.89B), while TransMedics Group Inc trades at $89.69 (market cap $3.10B). The key difference: National Beverage Corp. and TransMedics Group Inc are close in size by market cap, and TransMedics Group Inc is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.
| FIZZ | TMDX | |
|---|---|---|
Market Cap | $2.89B | $3.10B |
Sector | Consumer Cyclical | Technology |
52-Week High | $46.75 | $150.42 |
52-Week Low | $30.53 | $61.99 |
Enterprise Value | $2.60B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $32.13, up 0.53% today, with neutral technical signals and mixed earnings performance. The company reported $1.20B revenue and $186.82M net income for 2025, maintaining strong profitability margins. Recent news highlights a special $3.25 dividend announcement amid concerns about LaCroix brand stagnation and competitive pressures.
The stock faces headwinds from declining volumes and muted growth prospects, offset by shareholder returns via dividends. Analyst sentiment is cautious with 50% sell ratings. Key risks include consumer weakness and tariff impacts, while valuation at 15.84x P/E appears reasonable given current fundamentals.
TMDX trades at $83.89, up 4.59% today, with a bullish technical signal from moving averages and strong support at $81. The company reported a Q2 2026 earnings miss ($0.44 actual vs. $0.50 expected) but beat revenue expectations, with 2025 net income at $190.29M. Analyst consensus is a Buy with a $99.57 price target, though recent news highlights a legal investigation into fiduciary duties.
Outlook remains positive due to raised revenue guidance and institutional interest, but risks include earnings volatility, margin pressure, and legal scrutiny. The stock's valuation multiples suggest growth expectations, yet execution on cost control and international expansion will be critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
